Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

NEUROCRINE BIOSCIENCES INC Form 4 December 19, 2014 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **GORMAN KEVIN CHARLES** Issuer Symbol NEUROCRINE BIOSCIENCES (Check all applicable) INC [NBIX] (Last) (First) (Middle) 3. Date of Earliest Transaction _X_ Director 10% Owner X_Officer (give title Other (specify (Month/Day/Year) below) below) **NEUROCRINE** 12/18/2014 PRESIDENT AND CEO **BIOSCIENCES, 12780 EL CAMINO REAL** (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting SAN DIEGO, CA 92130 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of 6. Transaction(A) or Disposed of (D) Indirect Security (Month/Day/Year) Execution Date, if Securities Ownership (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Direct Beneficial anv (Month/Day/Year) (Instr. 8) Owned (D) or Ownership Following (Instr. 4) Indirect (I) Reported (Instr. 4) (A) Transaction(s) or (Instr. 3 and 4) Code V (D) Price Amount Common 12/18/2014 \$ 2.59 205,952 D Μ 25,000А Stock \$ Common S⁽³⁾ 23.24 12/18/2014 25,000 D 180,952 D Stock (4)Common 12/18/2014 Μ 30,000 Α \$ 5.12 210,952 D Stock 12/18/2014 S⁽³⁾ 30,000 D D Common \$ 180,952 Stock 23.24

Edgar Filing: NEUROCRINE BIOSCIENCES INC - Form 4

					(4)		
Common Stock	12/18/2014	М	15,000	А	\$ 5.12	195,952	D
Common Stock	12/19/2014	S <u>(3)</u>	15,000	D	\$ 24.01	180,952	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amour or Numbe of Shar
Nonqualified Stock Option	\$ 2.59	12/18/2014		М	25,000	<u>(1)</u>	05/11/2017	Common Stock	25,00
Incentive Stock Option	\$ 5.12	12/18/2014		М	15,526	(2)	02/27/2015	Common Stock	15,52
Nonqualified Stock Option	\$ 5.12	12/18/2014		М	14,474	(2)	02/27/2015	Common Stock	14,47
Incentive Stock Option	\$ 5.12	12/19/2014		М	15,000	(2)	02/27/2015	Common Stock	15,00

Reporting Owners

Reporting Owner Name / Address	Relationships						
	Director	10% Owner	Officer	Other			
GORMAN KEVIN CHARLES							
NEUROCRINE BIOSCIENCES	х		PRESIDENT AND CEO				
12780 EL CAMINO REAL	Λ		FRESIDENT AND CEO				
SAN DIEGO, CA 92130							

Signatures

Timothy P. Coughlin, By Power of

Attorney

**Signature of Reporting Person

12/19/2014 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option was granted May 11, 2010 and vested in 36 equal monthly installments beginning June 11, 2010.
- (2) The option was granted February 27, 2008 and vested in 36 equal monthly installments beginning March 27, 2008.
- The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted
 (3) by the Reporting Person at least 90 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending, canceling, suspending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$22.54 to \$23.97. The(4) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Represents a weighted average price. These shares were sold in multiple transactions at prices ranging from \$24.00 to \$24.06. The(5) Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.